Quality of life measured by EQ-5D at different treatment time points for coronary artery disease: protocol for a systematic review and meta-analysis

Abstract

IntroductionCardiovascular disease is estimated to affect 423 million people globally. It caused 18 million deaths in 2017 and is projected to cost US$1 trillion by 2030 worldwide. Coronary artery disease (CAD) is the most common type of cardiovascular disease; CAD treatments can affect patients’ quality of life. Valuations of quality of life or health utilities are important for economic evaluations to ascertain relative health benefit when comparing treatments, and can be expected to change for individuals over time. The purpose of this systematic review is to estimate the quality of life of patients with CAD reported through the EuroQol 5 Dimension (EQ-5D) questionnaire, from short to longer term time points following different treatments.Methods and analysisPubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews and the EuroQol website will be systematically searched from January 2003–March 2020. Published, peer-reviewed, English language studies assessing quality of life of patients with CAD using the EQ-5D will be included. One researcher will conduct the search; two researchers will independently screen titles and abstracts for potential inclusion. Full texts of potentially eligible studies will be retrieved for a second round of independent screening against inclusion and exclusion criteria by two researchers. The final list of included studies will be assessed for risk of bias using the RoB 2 and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools for randomised and non-randomised studies, respectively. Data extraction will be done by one researcher, with data extraction for a random 10% of included studies checked by a second researcher. Mean utility weights for individual studies will be combined using random effects model meta-analyses. A model will be run separately for each time point and treatment. Treatment time points of interest include baseline, 30 days, 6 months, 12–24 months and more than 24 months. Subgroup analysis of patients with diabetes who received interventional treatments—coronary artery bypass graft or percutaneous coronary intervention with or without stents, will be conducted for the same selected time points.Ethics and disseminationEthics approval is not required for systematic reviews. Results of the review will be disseminated via publication in a peer-reviewed journal.

Application of the EQ-5D in the Middle East: A Systematic Review Focusing on Patients Living in the Kingdom of Saudi Arabia

“…1 The EuroQol group set out to develop a brief and practical questionnaire that would allow researchers to compare different patient populations, 12 and many researchers have indeed applied EQ-5D to a range of diseases, treatments, and measurements. [13][14][15] Although some researchers have used the EQ-5D with a Middle Eastern population, much of the literature focuses on Western societies. 15 Healthcare Utilities should be calculated based on specific populations, considering that sociodemographic context could influence QoL scores.…”

Assessment of utility values and QALYs after primary PCI with DP-Xience and BP-Biomatrix stents

“…Utilities give us the individual’s preference for a particular health outcome. Moreover, utilities are also employed to calculate QALYs, which are used for economic evaluation [ 15 ].…”

“…It increases the rate of mortality as well as affects the HRQOL badly, and has a negative impact on the vitality, energy levels, psychosocial aspects and social interaction. CAD patients show a significant reduction in the levels of morbidity and mortality after percutaneous coronary intervention (PCI) [ 3 , 4 ]. Health as defined by the World Health Organization (WHO 1947) is “not merely the absence of disease but also the physical, mental and social welfare”.…”

“…[ 5 , 10 , 14 ]. EQ-5D-5L is the preferred instrument for evaluation of QoL by the National Institute of Health and Care Excellence (NICE) UK, the Canadian agency for drugs and technology in health (CADTH), the European network of technology assessment (EunetHTA) and other decision making bodies [ 15 , 16 ]. Utility values obtained by EQ-5D-5L questionnaire can be used for assessment of QALYs [ 3 ].…”

Reducing waste in collection of quality-of-life data through better reporting: a case study

“…Briefly, we undertook systematic searches of literature databases, for papers published from January 2003 to March 2020, assessing the quality-of-life of patients with coronary artery disease, using the EQ-5D. The review protocol was published prior to data collection [13,14]. The aim was to estimate the quality-of-life of patients with coronary artery disease at baseline and following different treatments including coronary artery bypass graft or percutaneous coronary intervention with or without stent, at 30 days, 6 months, 12-24 months and more than 24 months.…”